학술논문

Early CD8.sup.+-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT
Document Type
Report
Source
PLoS ONE. September 20, 2018, Vol. 13 Issue 9, e0204136
Subject
Lymphocytes -- Research
Graft vs. host disease -- Care and treatment
Hematopoietic stem cell transplantation -- Usage -- Patient outcomes
Health
Science and technology
Care and treatment
Usage
Research
Patient outcomes
Language
English
ISSN
1932-6203
Abstract
In this single-center study we retrospectively evaluated the impact of early reconstitution of different lymphocyte subsets on patient outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We found that CD8.sup.+ T-cell counts exceeding 50x10.sup.6 /l as early as on day 28 post-transplantation correlated significantly with decreased relapse risk, with three-year relapse rates of 17.0% and 55.6% (P = 0.002), but were also associated with severe acute and chronic GVHD. Incidence of grade III-IV acute GVHD was 30.5% for those with early CD8.sup.+ T-cell recovery compared to 2.1% for those with lower CD8.sup.+ T-cell counts on day 28 post-transplant (HR = 20.24, P = 0.004). Early CD8.sup.+ T-cell reconstitution did not, however, affect the overall survival. Multivariate analysis showed that slow CD8.sup.+ T-cell reconstitution was strongly associated with increased risk of relapse (HR = 3.44, P = 0.026). A weaker correlation was found between CD4.sup.+ reconstitution and relapse-risk, but there was no such association with CD19.sup.+ B-cells or NK-cells. In conclusion, the early CD8.sup.+ T-cell recovery on day 28 post-transplant is associated with the lower risk of relapse but also predicts the impending severe GVHD, and thus could be useful in guiding timely treatment decisions.
Author(s): Juha Ranti 1,*, Samu Kurki 2, Urpu Salmenniemi 1, Mervi Putkonen 1, Soile Salomäki 1, Maija Itälä-Remes 1 Introduction Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an intensive treatment [...]